2016 Biomax Symposium: Bringing big and complex data into clinical practice

24 June 2016, Martinsried, Germany.
Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsried (near Munich), Germany. This year's Biomax Symposium focuses on how clinical practice and patient treatment can benefit from big and complex data. It will cover the challenges and requirements that need to be addressed in a clinical setting: from gathering big data, guaranteeing data security in daily practice and fostering feedback between complex clinical data and research, to learning from the data to make better treatment decisions. In a nutshell, the symposium will cover using big and complex data to treat the individual with the knowledge of all.

Biomax has hosted this biennial event since 2012 to facilitate the discussion between clinical management and practitioners, pharma, "Big Data" researchers, health insurance payers, public health and government representatives, funding providers, as well as patient representatives. Through the symposium Biomax hopes to share their own and other experiences in implementing such programs. Past symposia have been a popular forum for these important players to learn from each other and discuss the way forward.

Invited speakers and panel discussion participants are leaders from clinical research, healthcare organizations, international research projects and government. The opening session includes presentations by:

  • Prof. Dr. Emiel Wouters, Department of Respiratory Medicine, University Medical Centre, Maastricht
  • Henning Schneider, CIO at the University Medical Center Hamburg-Eppendorf
  • Prof. Dr. Hans-Werner Mewes, School of Life Sciences, Technische Universität München

The symposium is free of charge.

For further information and to register, please visit:
http://www.biomax.com/symposiums/biomax-symposium-2016/

About Biomax
Biomax Informatics AG is a leader in the development of computational solutions for the life sciences. Biomax provides the BioXM™ Knowledge Management Environment and other computational solutions, including the Viscovery® data-mining technology, for better decision making and knowledge management in biomarker identification, patient stratification and targeted medicine. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes medical clinics, research organizations and companies that are successful in drug discovery, diagnostics, fine chemicals, food and plant production and healthcare.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...